title: Comparison of the antidiabetic effects of linagliptin among groups with a normal renal function and a mild or severe renal impairment - retrospective observation study of Japanese patients with type 2 diabetes mellitus.
abstract: OBJECTIVE
  The clinical course > 6 months after the initiation of linagliptin in patients with type 2 diabetes was compared among the groups divided by their renal function.
  
  
  METHODS
  Two hundred and sixteen Japanese patients with type 2 diabetes treated with 5 mg once daily linagliptin were studied as the treated set. One hundred and forty-five subjects whose medications were not changed during the observation period were investigated as the full analysis set to assess the effectiveness. The subjects were divided into three groups based on an eGFR: eGFR ≥ 60, 59 - 45 and < 45 ml/min/1.73 m(2). The parameters were analyzed separately in the patients receiving monotherapy and additional therapy of linagliptin.
  
  
  RESULTS
  The HbA1c (NGSP) levels significantly improved in both the patients receiving monotherapy and additional therapy. The changes in the HbA1c levels at 6 months were not significantly different between the groups with an eGFR ≥ 60, 59 - 45 and < 45 ml/min/1.73 m(2) receiving monotherapy (-1.0, -0.8 and -0.8%, respectively). Similarly, those were not significantly different between the different groups receiving additional therapy (-0.6, -0.5 and -0.7%, respectively).
  
  
  CONCLUSIONS
  Linagliptin is considered to be effective for patients with type 2 diabetes and renal impairment in the present analysis performed at our institution.
authors.affiliation: Edogawa Hospital, Department of Diabetes, Metabolism and Kidney Disease , 2-24-18, Higashikoiwa, Edogawa-ku, Tokyo, 133-0052 , Japan +81 3 3673 1221 ; +81 3 3673 1229 ; ito@edogawa.or.jp.
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Ito
authors.forename: Mariko
authors.initials: M
authors.lastname: Abe
authors.forename: Shinichi
authors.initials: S
authors.lastname: Antoku
authors.forename: Takashi
authors.initials: T
authors.lastname: Omoto
authors.forename: Masahiro
authors.initials: M
authors.lastname: Shinozaki
authors.forename: Shinya
authors.initials: S
authors.lastname: Nishio
authors.forename: Mizuo
authors.initials: M
authors.lastname: Mifune
authors.forename: Michiko
authors.initials: M
authors.lastname: Togane
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D044466:Asian People; D016022:Case-Control Studies; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005919:Glomerular Filtration Rate; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000069476:Linagliptin; D008297:Male; D011687:Purines / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D051437:Renal Insufficiency / Q000150:complications / Q000503:physiopathology*; D012189:Retrospective Studies
chemical_list: D007004:Hypoglycemic Agents; D011687:Purines; D011799:Quinazolines; D000069476:Linagliptin
keywords: adherence; antiproteinuric effect; dipeptidyl peptidase-4 inhibitor; linagliptin; renal impairment; type 2 diabetes mellitus